metreleptin (Myalept®)


Indications for Prior Authorization:

  • Adjunct therapy to diet for treatment of leptin deficiency in patients with congenital or acquired lipodystrophy

Patients must meet the following criteria for the indications above:

  • Patient must have generalized lipodystrophy with inadequate leptin secreted by adipocytes

The drug is not approved for any use not mentioned above including:

  • Human immunodeficiency virus related lipodystrophy
  • Liver disease
  • Partial lipodystrophy


  • Patients less than 40 kg the starting dose is 0.06 mg/kg SC once daily
  • For males greater than 40 kg the dose is 2.5 mg SC once daily
  • For females greater than 40 kg the dose is 5 mg SC once daily
  • Titrate based on clinical response
  • Max dose patients < 40 kg is 0.13 mg/kg/day
  • Max dose patients >40 kg is 10 mg/day


One year


Last review date: May 5, 2014

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar